These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 20955264)

  • 21. Hot flashes during androgen deprivation therapy with luteinizing hormone-releasing hormone agonist combined with steroidal or nonsteroidal antiandrogen for prostate cancer.
    Sakai H; Igawa T; Tsurusaki T; Yura M; Kusaba Y; Hayashi M; Iwasaki S; Hakariya H; Hara T; Kanetake H
    Urology; 2009 Mar; 73(3):635-40. PubMed ID: 19038426
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment of bicalutamide-induced breast events.
    Sieber PR
    Expert Rev Anticancer Ther; 2007 Dec; 7(12):1773-9. PubMed ID: 18062751
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Use of the nonsteroidal anti-androgen Casodex in advanced prostatic carcinoma.
    Kennealey GT; Furr BJ
    Urol Clin North Am; 1991 Feb; 18(1):99-110. PubMed ID: 1992575
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bicalutamide-induced gynaecomastia: do we have the answer?
    Di Lorenzo G; Autorino R
    Eur Urol; 2007 Jul; 52(1):5-8. PubMed ID: 17258386
    [No Abstract]   [Full Text] [Related]  

  • 25. Hormonal therapy of prostate cancer.
    Labrie F
    Prog Brain Res; 2010; 182():321-41. PubMed ID: 20541672
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of sexual and erectile dysfunction and response to treatment in patients receiving androgen deprivation therapy for prostate cancer.
    DiBlasio CJ; Malcolm JB; Derweesh IH; Womack JH; Kincade MC; Mancini JG; Ogles ML; Lamar KD; Patterson AL; Wake RW
    BJU Int; 2008 Jul; 102(1):39-43. PubMed ID: 18294309
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration.
    Tyrrell CJ; Iversen P; Tammela T; Anderson J; Björk T; Kaisary AV; Morris T
    BJU Int; 2006 Sep; 98(3):563-72. PubMed ID: 16771791
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A case of male breast cancer in association with bicalutamide-induced gynaecomastia.
    Chianakwalam CI; McCahy P; Griffiths NJ
    Breast; 2005 Apr; 14(2):163-4. PubMed ID: 15767188
    [No Abstract]   [Full Text] [Related]  

  • 29. Anti-androgens increase N-terminal pro-BNP levels in men with prostate cancer.
    Dockery F; Bulpitt CJ; Agarwal S; Vernon C; Nihoyannopoulos P; Kemp M; Hooper J; Rajkumar C
    Clin Endocrinol (Oxf); 2008 Jan; 68(1):59-65. PubMed ID: 17692108
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Salvage therapy with bicalutamide 150 mg in nonmetastatic castration-resistant prostate cancer.
    Lodde M; Lacombe L; Fradet Y
    Urology; 2010 Nov; 76(5):1189-93. PubMed ID: 20303155
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Patterns of Bicalutamide Use in Prostate Cancer Treatment: A U.S. Real-World Analysis Using the SEER-Medicare Database.
    Beebe-Dimmer JL; Ruterbusch JJ; Bylsma LC; Gillezeau C; Fryzek J; Schultz NM; Flanders SC; Barlev A; Heath E; Quek RGW
    Adv Ther; 2018 Sep; 35(9):1438-1451. PubMed ID: 29946798
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A dramatic, objective antiandrogen withdrawal response: case report and review of the literature.
    Lau YK; Chadha MK; Litwin A; Trump DL
    J Hematol Oncol; 2008 Nov; 1():21. PubMed ID: 18986533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anaemia following initiation of androgen deprivation therapy for metastatic prostate cancer: a retrospective chart review.
    Curtis KK; Adam TJ; Chen SC; Pruthi RK; Gornet MK
    Aging Male; 2008 Dec; 11(4):157-61. PubMed ID: 18937151
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alternative nonsteroidal antiandrogen therapy for advanced prostate cancer that relapsed after initial maximum androgen blockade.
    Suzuki H; Okihara K; Miyake H; Fujisawa M; Miyoshi S; Matsumoto T; Fujii M; Takihana Y; Usui T; Matsuda T; Ozono S; Kumon H; Ichikawa T; Miki T;
    J Urol; 2008 Sep; 180(3):921-7. PubMed ID: 18635218
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Eliciting patient preferences for hormonal therapy options in the treatment of metastatic prostate cancer.
    Lloyd A; Penson D; Dewilde S; Kleinman L
    Prostate Cancer Prostatic Dis; 2008; 11(2):153-9. PubMed ID: 17637761
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bicalutamide-associated fulminant hepatotoxicity.
    O'Bryant CL; Flaig TW; Utz KJ
    Pharmacotherapy; 2008 Aug; 28(8):1071-5. PubMed ID: 18657023
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Exploratory study of drug plasma levels during bicalutamide 150 mg therapy co-administered with tamoxifen or anastrozole for prophylaxis of gynecomastia and breast pain in men with prostate cancer.
    Boccardo F; Rubagotti A; Conti G; Potenzoni D; Manganelli A; Del Monaco D
    Cancer Chemother Pharmacol; 2005 Oct; 56(4):415-20. PubMed ID: 15838655
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Profound bicalutamide withdrawal syndrome in a hormone-refractory T4N1 prostate cancer permitting both salvage radiotherapy and cessation of hormonal therapy.
    Takeshita H; Kawakami S; Fukui I
    Int J Urol; 2009 Mar; 16(3):337-8. PubMed ID: 19298352
    [No Abstract]   [Full Text] [Related]  

  • 39. [The use of Casodex (bicalutamide) in the treatment of disseminated prostatic cancer].
    Sivko AV; Prokhorov AV
    Urol Nefrol (Mosk); 1997; (3):49-52. PubMed ID: 9245060
    [No Abstract]   [Full Text] [Related]  

  • 40. [The role of bicalutamide in the treatment of prostate cancer].
    Stav SY; Segal G
    Harefuah; 2002 Apr; 141(4):379-83, 408, 407. PubMed ID: 12017896
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.